Follow the people · Insider
Brian J.G. Pereira
Brian J.G. Pereira files insider transactions with the SEC as a director of Prokidney (PROK). We hold 3 disclosed purchases and sales filed since 9 February 2006, 3 of them in the last 90 days.
- Files forPROK
- Disclosed buys and sells3 in all, 3 in the last 90 days
- Last disclosure20 August 2026
Positions held
6 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 11 July 2022 — 20 August 2026Director · Prokidney (PROK)28 Form 4 lines · source: SEC Form 4
- Filed 1 February 2019 — 11 June 2026Director · KalVista Pharmaceuticals (KALV)14 Form 4 lines · source: SEC Form 4
- Filed 15 April 2020 — 15 April 2020Executive Chairman · Abeona Therapeutics (ABEO)1 Form 4 line · source: SEC Form 4
- Filed 20 November 2007 — 4 March 2014Director · Biodel (BIOD)16 Form 4 lines · source: SEC Form 4
- Filed 7 November 2006 — 1 March 2011President and CEO · Amag Pharmaceuticals (AMAG)84 Form 4 lines · source: SEC Form 4
- Filed 7 February 2006 — 11 May 2006President · Advanced Magnetics (AVM)4 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 229,338 shares of ProkidneySEC Form 420 August 2026Class A Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▼ sold on the open market 27,826 shares of ProkidneySEC Form 420 August 2026Class A Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▼ sold on the open market 222,949 shares of ProkidneySEC Form 420 August 2026Class A Common Stock · traded 19 August 2026 · filed 20 August 2026
- ▼ sold on the open market 27,051 shares of ProkidneySEC Form 420 August 2026Class A Common Stock · traded 19 August 2026 · filed 20 August 2026
- ▼ sold on the open market 222,948 shares of ProkidneySEC Form 420 August 2026Class A Common Stock · traded 20 August 2026 · filed 20 August 2026
- ▼ sold on the open market 27,052 shares of ProkidneySEC Form 420 August 2026Class A Common Stock · traded 20 August 2026 · filed 20 August 2026
- converted 81,929 shares of ProkidneySEC Form 46 August 2026Class A Common Stock · traded 4 August 2026 · filed 6 August 2026
- converted 675,235 shares of ProkidneySEC Form 46 August 2026Class A Common Stock · traded 4 August 2026 · filed 6 August 2026
- converted 81,929 shares of Prokidney (a derivative holding)SEC Form 46 August 2026Class B Common Stock · traded 4 August 2026 · filed 6 August 2026
- converted 81,929 shares of Prokidney (a derivative holding)SEC Form 46 August 2026Common Units in ProKidney Holdings, LLC · traded 4 August 2026 · filed 6 August 2026
- converted 675,235 shares of Prokidney (a derivative holding)SEC Form 46 August 2026Class B Common Stock · traded 4 August 2026 · filed 6 August 2026
- converted 675,235 shares of Prokidney (a derivative holding)SEC Form 46 August 2026Common Units in ProKidney Holdings, LLC · traded 4 August 2026 · filed 6 August 2026
- returned to the issuer 14,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 11 June 2026
- returned to the issuer 7,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 11 June 2026
- returned to the issuer 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 11 June 2026
- returned to the issuer 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 11 June 2026
- returned to the issuer 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 11 June 2026
- returned to the issuer 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 11 June 2026
- returned to the issuer 30,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 411 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 11 June 2026
- was granted 135,000 shares of Prokidney (a derivative holding)SEC Form 429 May 2026Director stock option (right to buy) · traded 28 May 2026 · filed 29 May 2026
- ▼ sold on the open market 227,431 shares of ProkidneySEC Form 414 November 2025Class A Common Stock · traded 12 November 2025 · filed 14 November 2025
- ▼ sold on the open market 27,595 shares of ProkidneySEC Form 414 November 2025Class A Common Stock · traded 12 November 2025 · filed 14 November 2025
- ▼ sold on the open market 447,803 shares of ProkidneySEC Form 414 November 2025Class A Common Stock · traded 13 November 2025 · filed 14 November 2025
- ▼ sold on the open market 54,333 shares of ProkidneySEC Form 414 November 2025Class A Common Stock · traded 13 November 2025 · filed 14 November 2025
- was granted 30,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 42 October 2025Stock Option (right to buy) · traded 1 October 2025 · filed 2 October 2025
- was granted 125,862 shares of Prokidney (a derivative holding)SEC Form 42 June 2025Director stock option (right to buy) · traded 29 May 2025 · filed 2 June 2025
- converted 81,928 shares of Prokidney (a derivative holding)SEC Form 46 February 2025Class B Ordinary Shares · traded 4 February 2025 · filed 6 February 2025
- converted 81,928 shares of Prokidney (a derivative holding)SEC Form 46 February 2025Common Units in ProKidney LP · traded 4 February 2025 · filed 6 February 2025
- converted 675,234 shares of Prokidney (a derivative holding)SEC Form 46 February 2025Class B Ordinary Shares · traded 4 February 2025 · filed 6 February 2025
- converted 675,234 shares of Prokidney (a derivative holding)SEC Form 46 February 2025Common Units in ProKidney LP · traded 4 February 2025 · filed 6 February 2025
- converted 81,928 shares of ProkidneySEC Form 46 February 2025Class A Ordinary Shares · traded 4 February 2025 · filed 6 February 2025
- converted 675,234 shares of ProkidneySEC Form 46 February 2025Class A Ordinary Shares · traded 4 February 2025 · filed 6 February 2025
- was granted 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 44 October 2024Stock Option (Right to Buy) · traded 3 October 2024 · filed 4 October 2024
- was granted 62,558 shares of Prokidney (a derivative holding)SEC Form 43 June 2024Director stock option (right to buy) · traded 30 May 2024 · filed 3 June 2024
- was granted 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 428 September 2023Stock Option (right to buy) · traded 26 September 2023 · filed 28 September 2023
- was granted 48,128 shares of Prokidney (a derivative holding)SEC Form 43 July 2023Director stock option (right to buy) · traded 29 June 2023 · filed 3 July 2023
- was granted 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 417 October 2022Employee Stock Option (right to buy) · traded 13 October 2022 · filed 17 October 2022
- was granted 1,514,326 shares of Prokidney (a derivative holding)SEC Form 413 July 2022Class B Ordinary Shares · traded 11 July 2022 · filed 13 July 2022
- was granted 1,514,326 shares of Prokidney (a derivative holding)SEC Form 413 July 2022Common Units in ProKidney LP · traded 11 July 2022 · filed 13 July 2022
- was granted 10,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 41 October 2021Director Stock Option (Right to Buy) · traded 30 September 2021 · filed 1 October 2021
- was granted 7,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 42 October 2020Director Stock Option (right to buy) · traded 1 October 2020 · filed 2 October 2020
- was granted 930,000 shares of Abeona Therapeutics (a derivative holding)SEC Form 417 April 2020Employee Stock Option (right to buy) · traded 15 April 2020 · filed 17 April 2020
- was granted 14,000 shares of KalVista Pharmaceuticals (a derivative holding)SEC Form 45 February 2019Director Stock Option (Right to Buy) · traded 1 February 2019 · filed 5 February 2019
- was granted 10,000 shares of Biodel (a derivative holding)SEC Form 46 March 2014Stock Option (right to buy) · traded 4 March 2014 · filed 6 March 2014
- ▼ sold on the open market 4,734 shares of BiodelSEC Form 423 December 2013Common Stock · traded 20 December 2013 · filed 23 December 2013
- was granted 5,000 shares of Biodel (a derivative holding)SEC Form 46 March 2013Stock Option (right to buy) · traded 5 March 2013 · filed 6 March 2013
- was granted 20,000 shares of Biodel (a derivative holding)SEC Form 49 March 2012Stock Option (right to buy) · traded 8 March 2012 · filed 9 March 2012
- ▼ sold on the open market 15,000 shares of BiodelSEC Form 420 December 2011Common Stock · traded 16 December 2011 · filed 20 December 2011
- exercised options over 3,937 shares of Biodel (a derivative holding)SEC Form 44 October 2011Restricted Stock Units · traded 30 September 2011 · filed 4 October 2011
- exercised options over 3,937 shares of BiodelSEC Form 44 October 2011Common Stock · traded 30 September 2011 · filed 4 October 2011
- converted 3,958 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 42 March 2011Restricted Stock Unit · traded 1 March 2011 · filed 2 March 2011
- converted 3,958 shares of Amag PharmaceuticalsSEC Form 42 March 2011Common Stock · traded 1 March 2011 · filed 2 March 2011
- ▼ sold on the open market 3,958 shares of Amag PharmaceuticalsSEC Form 42 March 2011Common Stock · traded 1 March 2011 · filed 2 March 2011
- was granted 20,000 shares of Biodel (a derivative holding)SEC Form 42 March 2011Stock Option (right to buy) · traded 1 March 2011 · filed 2 March 2011
- was granted 75,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 411 January 2011Restricted stock unit · traded 8 January 2011 · filed 11 January 2011
- was granted 125,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 411 January 2011Restricted stock unit · traded 8 January 2011 · filed 11 January 2011
- was granted 3,937 shares of Biodel (a derivative holding)SEC Form 45 October 2010Restricted Stock Units · traded 1 October 2010 · filed 5 October 2010
- converted 5,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 43 May 2010Restricted Stock Unit · traded 30 April 2010 · filed 3 May 2010
- converted 5,000 shares of Amag PharmaceuticalsSEC Form 43 May 2010Common Stock · traded 30 April 2010 · filed 3 May 2010
- was granted 20,000 shares of Biodel (a derivative holding)SEC Form 43 March 2010Stock Option (right to buy) · traded 2 March 2010 · filed 3 March 2010
- was granted 47,500 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 425 February 2010Stock Options · traded 24 February 2010 · filed 25 February 2010
- was granted 15,833 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 425 February 2010Restricted Stock Unit · traded 24 February 2010 · filed 25 February 2010
- exercised options over 55,300 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 412 November 2009Employee Stock Options (Right to Buy) · traded 9 November 2009 · filed 12 November 2009
- exercised options over 50,744 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 412 November 2009Employee Stock Options (Right to Buy) · traded 9 November 2009 · filed 12 November 2009
- exercised options over 8,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 412 November 2009Employee Stock Options (Right to Buy) · traded 9 November 2009 · filed 12 November 2009
- exercised options over 15,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 412 November 2009Employee Stock Options (Right to Buy) · traded 10 November 2009 · filed 12 November 2009
- exercised options over 8,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 412 November 2009Employee Stock Options (Right to Buy) · traded 10 November 2009 · filed 12 November 2009
- exercised options over 60,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 412 November 2009Employee Stock Option (Right to Buy) · traded 10 November 2009 · filed 12 November 2009
- exercised options over 55,300 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 9 November 2009 · filed 12 November 2009
- ▼ sold on the open market 55,300 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 9 November 2009 · filed 12 November 2009
- exercised options over 50,744 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 9 November 2009 · filed 12 November 2009
- ▼ sold on the open market 50,744 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 9 November 2009 · filed 12 November 2009
- ▼ sold on the open market 32,967 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 9 November 2009 · filed 12 November 2009
- exercised options over 8,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 9 November 2009 · filed 12 November 2009
- ▼ sold on the open market 8,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 9 November 2009 · filed 12 November 2009
- exercised options over 15,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 10 November 2009 · filed 12 November 2009
- ▼ sold on the open market 15,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 10 November 2009 · filed 12 November 2009
- exercised options over 8,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 10 November 2009 · filed 12 November 2009
- ▼ sold on the open market 8,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 10 November 2009 · filed 12 November 2009
- exercised options over 60,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 10 November 2009 · filed 12 November 2009
- ▼ sold on the open market 60,000 shares of Amag PharmaceuticalsSEC Form 412 November 2009Common Stock · traded 10 November 2009 · filed 12 November 2009
- converted 5,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 45 August 2009Restricted Stock Unit · traded 3 August 2009 · filed 5 August 2009
- converted 5,000 shares of Amag PharmaceuticalsSEC Form 45 August 2009Common Stock · traded 3 August 2009 · filed 5 August 2009
- ▼ sold on the open market 4,900 shares of Amag PharmaceuticalsSEC Form 45 August 2009Common Stock · traded 5 August 2009 · filed 5 August 2009
- ▼ sold on the open market 100 shares of Amag PharmaceuticalsSEC Form 45 August 2009Common Stock · traded 5 August 2009 · filed 5 August 2009
- was granted 20,000 shares of Biodel (a derivative holding)SEC Form 45 March 2009Common Stock · traded 3 March 2009 · filed 5 March 2009
- was granted 270,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 426 February 2009Stock Options · traded 25 February 2009 · filed 26 February 2009
- was granted 50,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 47 August 2008Restricted Stock Unit · traded 5 August 2008 · filed 7 August 2008
- was granted 2,877 shares of Biodel (a derivative holding)SEC Form 44 March 2008Common Stock · traded 28 February 2008 · filed 4 March 2008
- ▲ bought on the open market 30,000 shares of BiodelSEC Form 414 February 2008Common Stock · traded 12 February 2008 · filed 14 February 2008
- gave away 30,000 shares of BiodelSEC Form 414 February 2008Common Stock · traded 12 February 2008 · filed 14 February 2008
- exercised options over 5,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 411 February 2008Restricted Stock Unit · traded 7 February 2008 · filed 11 February 2008
- exercised options over 5,000 shares of Amag PharmaceuticalsSEC Form 411 February 2008Common Stock · traded 7 February 2008 · filed 11 February 2008
- ▼ sold on the open market 5,000 shares of Amag PharmaceuticalsSEC Form 411 February 2008Common Stock · traded 8 February 2008 · filed 11 February 2008
- was granted 25,000 shares of Biodel (a derivative holding)SEC Form 430 November 2007Employee Stock Option (right to buy) · traded 20 November 2007 · filed 30 November 2007
- was granted 25,000 shares of Biodel (a derivative holding)SEC Form 426 November 2007Employee Stock Option (right to buy) · traded 21 November 2007 · filed 26 November 2007
- exercised options over 10,989 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 419 November 2007Employee Stock Options (Right to Buy) · traded 16 November 2007 · filed 19 November 2007
- exercised options over 10,989 shares of Amag PharmaceuticalsSEC Form 419 November 2007Common Stock · traded 16 November 2007 · filed 19 November 2007
- exercised options over 10,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 42 October 2007Employee Stock Options (Right to Buy) · traded 1 October 2007 · filed 2 October 2007
- exercised options over 10,000 shares of Amag PharmaceuticalsSEC Form 42 October 2007Common Stock · traded 1 October 2007 · filed 2 October 2007
- ▼ sold on the open market 10,000 shares of Amag PharmaceuticalsSEC Form 42 October 2007Common Stock · traded 1 October 2007 · filed 2 October 2007
- exercised options over 45,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 427 September 2007Employee Stock Options (Right to Buy) · traded 25 September 2007 · filed 27 September 2007
- exercised options over 20,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 46 September 2007Employee Stock Options (Right to Buy) · traded 4 September 2007 · filed 6 September 2007
- exercised options over 20,000 shares of Amag PharmaceuticalsSEC Form 46 September 2007Common Stock · traded 4 September 2007 · filed 6 September 2007
- ▼ sold on the open market 8,500 shares of Amag PharmaceuticalsSEC Form 46 September 2007Common Stock · traded 4 September 2007 · filed 6 September 2007
- ▼ sold on the open market 11,500 shares of Amag PharmaceuticalsSEC Form 46 September 2007Common Stock · traded 5 September 2007 · filed 6 September 2007
- exercised options over 21,978 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 42 August 2007Employee Stock Options (Right to Buy) · traded 31 July 2007 · filed 2 August 2007
- exercised options over 20,000 shares of Amag Pharmaceuticals (a derivative holding)SEC Form 42 August 2007Employee Stock Options (Right to Buy) · traded 1 August 2007 · filed 2 August 2007
- exercised options over 21,978 shares of Amag PharmaceuticalsSEC Form 42 August 2007Common Stock · traded 31 July 2007 · filed 2 August 2007
- exercised options over 20,000 shares of Amag PharmaceuticalsSEC Form 42 August 2007Common Stock · traded 1 August 2007 · filed 2 August 2007
- ▼ sold on the open market 4,800 shares of Amag PharmaceuticalsSEC Form 42 August 2007Common Stock · traded 1 August 2007 · filed 2 August 2007
- ▼ sold on the open market 15,200 shares of Amag PharmaceuticalsSEC Form 42 August 2007Common Stock · traded 2 August 2007 · filed 2 August 2007
- exercised options over 20,000 shares of Advanced Magnetics (a derivative holding)SEC Form 45 July 2007Employee Stock Options (Right to Buy) · traded 3 July 2007 · filed 5 July 2007
- exercised options over 20,000 shares of Advanced MagneticsSEC Form 45 July 2007Common Stock · traded 3 July 2007 · filed 5 July 2007
- ▼ sold on the open market 12,000 shares of Advanced MagneticsSEC Form 45 July 2007Common Stock · traded 3 July 2007 · filed 5 July 2007
- ▼ sold on the open market 8,000 shares of Advanced MagneticsSEC Form 45 July 2007Common Stock · traded 5 July 2007 · filed 5 July 2007
- ▼ sold on the open market 3,157 shares of Advanced MagneticsSEC Form 420 June 2007Common Stock · traded 12 June 2007 · filed 20 June 2007
- exercised options over 15,000 shares of Advanced Magnetics (a derivative holding)SEC Form 46 June 2007Employee Stock Options (Right to Buy) · traded 4 June 2007 · filed 6 June 2007
- exercised options over 15,000 shares of Advanced MagneticsSEC Form 46 June 2007Common Stock · traded 4 June 2007 · filed 6 June 2007
- ▼ sold on the open market 15,000 shares of Advanced MagneticsSEC Form 46 June 2007Common Stock · traded 4 June 2007 · filed 6 June 2007
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.